Abbott Laboratories (ABT) Earnings Call Transcripts

Abbott Laboratories's Latest Earnings Call - Q3 FY2026

In Abbott Laboratories' (ABT:US) Q3 2026 earnings call, the company reported a 7% increase in sales and a 9% rise in earnings per share (EPS), signaling a positive acceleration in growth compared to earlier quarters. A significant announcement was the planned spin-off of the Nutrition business into a separate publicly traded entity, expected to enhance both companies' strategic focus and operational effectiveness. Management maintained guidance for Q4 adjusted EPS in the range of $1.62 to $1.67, while projecting a revenue growth reduction to approximately 6% for the fiscal year, implying about 8% growth in Q4.

Reported metrics

Guidance from management

Management expects Q4 adjusted EPS in the range of $1.62 to $1.67 and has lowered full-year revenue growth guidance to approximately 6%. They anticipate that the separation will enhance Abbott's growth profile moving forward.

What management said

Yes. I get that you guys are going to start to try and triangulate as much as you can there. Like I said, I'm not going to give, kind of, total guidance from -- on this call. We're probably going to do that in January. All I'll say is, I mean, I gave you a little bit in terms of how we're thinking about our top line. But like I said, we're going to have EPS growth. We're going to have gross margin expansion. We're go...

Thank you all for your questions. This now concludes Abbott's conference call. A webcast replay of this call will be available after 11:00 a.m. Central Time today on our website at abbott.com. Thank you all for joining us.

What analysts pressed on

Analysts expressed concerns regarding the revenue guidance reduction and the impact of short-term headwinds in key segments like EP and diabetes. There were also inquiries about the implications of the Nutrition spin-off on Abbott's overall strategic direction and potential M&A activities.

Main topics on the call

• Nutrition Business Spin-Off — Abbott announced its intention to separate its Nutrition business into an independent publicly traded company, which is expected to enhance value creation for both entities. CEO Robert Ford stated, "We believe both busin...
• Sales and Earnings Growth — Sales grew by 7% and EPS increased by 9% in Q3 2026, indicating a strong performance. Ford noted, "We delivered an acceleration in growth on both top and bottom lines," highlighting improved momentum compared to prior qu...
• Diagnostics Performance — Diagnostics sales grew 6.5%, driven by core laboratory and cancer diagnostics. Ford mentioned, "In cancer diagnostics, sales growth of 14% was driven by Cologuard," indicating strong demand in this segment.
• Guidance Update — Management lowered its full-year revenue growth guidance to approximately 6%, reflecting challenges in the Electrophysiology (EP) and diabetes segments. Ford explained, "The reduction in Q4... implies just north of 8%, w...

Read the full Abbott Laboratories transcript (Q3 FY2026) → Summary generated from the call transcript; every figure above is stated by management on the record.

Earnings Call History

EarningsCalls.dev has 33 Abbott Laboratories earnings call transcripts on record, spanning January 14, 2020 to October 21, 2026. Based on this history, Abbott Laboratories reports quarterly. The most recent call on file is dated October 21, 2026. The full list is below — each row opens the complete, free-to-read transcript.

Ticker

ABT

Exchange

NYSE

Country

US

Sector

Health Care

Industry

Health Care Equipment and Supplies

Calls on record

33

First call

January 14, 2020

Most recent

October 21, 2026

Reporting cadence

quarterly